Department of Surgery I,
Correspondence Address: Dr. Kazunori Shibao, Department of Surgery I, School of Medicine, University of Occupational and Environmental Health Japan 1-1 Iseigaoka, Yahatanishi-ward, Kitakyushu 807-8555, Japan. E-mail: email@example.com
© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The incidence of esophagogastric junction (EGJ) cancer is increasing in the world. EGJ cancer is traditionally classified by the Siewert classification, despite its limitations. The definition and classification of EGJ cancer is a controversial topic. Thus, the best available strategy for the surgical treatment of EGJ cancer remains controversial. This chapter reviews a minimally invasive approaches for EGJ cancer. Most operations for EGJ cancer that are performed by open surgery can be performed minimally invasively. A minimally invasive transthoracic approach (Ivor-Lewis or McKeown esophagectomy) is the optimal surgical approach for Siewert type I cancer. Mediastinoscope-assisted transhiatal esophagectomy, which was recently reported, may be a suitable surgical option, especially for frail patients with Siewert type I cancer. Generally, laparoscopic total or proximal gastrectomy is regarded as the standard for surgerical method for Siewert type III cancer, while both laparoscopic gastrectomy (with lower esophagectomy) or a minimally invasive Ivor-Lewis approach are recommended for Siewert type II cancer. Minimally invasive surgery (MIS) has the potential to shorten the length of hospitalization, reduce the risk of postoperative pulmonary complications, and improve quality of life with a similar margin status, nodal harvest, and survival rate to open techniques. However, as the existing literature is still limited, the choice of surgical method should be judged by the experienced surgeons, especially in MIS. This review reveals that further large clinical stuidies are need to deepen our understanding of MIS for EGJ cancer.
Esophagogastric junction cancer, thoraco-abdominal approach, transhiatal approach, minimally invasive esophagectomy
Esophageal cancer and gastric cancer are among the most common malignancies worldwide, and are a main causes of cancer-related mortality. The term “esophagogastric junction (EGJ) tumor” refers to a tumor that arises close to the esophagogastric junction. The incidence of EGJ cancer has dramatically increased in the last decade. In Eastern countries, westernized lifestyle habits, Helicobacter pylori infection, obesity, a combination of alcohol and smoking, and the increased incidence of gastroesophageal reflux disease are thought to be possible reasons.
EGJ cancers are traditionally classified into one of the three categories of the Siewert system, which is the most commonly used classification system, based on the location of the epicenter of the given tumor.
Type I: Adenocarcinoma of the distal esophagus with the center located within 1 to 5 cm above the anatomic EGJ. Type II: True carcinoma of the cardia infiltrating from 1 cm on the side of the esophagus up to 2 cm below the GEJ in the stomach. Type III: Subcardial gastric carcinoma with the tumor center between 2 and 5 cm below the GEJ.
Meanwhile, in the Japanese Classification of Gastric Carcinoma, EGJ cancer has been defined as cancer with its center located within 2 cm of the EGJ since 1972. In 2012, the Japanese Gastric Cancer Association and Japan Esophageal Society joint force conducted a nationwide surveillance of EGJ cancer of < 4 cm in diameter, which included the retrospective data of 3,177 patients from 273 institutions. The joint force presented an algorithm showing the tentative standard in the extent of lymphadenectomy, based on this surveillance, in Japanese Gastric Cancer Treatment Guidelines, 2014 (ver. 4). Similarly, the American Joint Committee on Cancer (AJCC) has changed the definition of EGJ cancer to a cancer whose epicenter is within the proximal 2 cm of the cardia (Siewert I/II) in the eighth edition of the TNM classification. However, they categorized EGJ cancer as an esophageal cancer and staged it accordingly. Meanwhile, The National Comprehensive Cancer Network, recommends that Siewert type III tumors should be treated as gastric cancers, since their lymph nodal flow and prognosis are different from Siewert type I and type II cancers. Thus, a current concern of surgeons is whether Siewert type II and III cancer should be regarded-and thus surgically approached-as the same tumor. The lack of consensus regarding the definition of EGJ cancer and the classification scheme that could affect the standard of care for this category contribute to this controversy.
Minimally invasive surgery have been gaining popularity in recent years. Cuschieri et al. first described the successful performance of thoracoscopic esophagectomy for esophageal cancer in 1992, and several authors have reported their experience with good results[9,10]. The first laparoscopy-assisted distal gastrectomy was reported by Kitano et al. Thereafter, many clinical trials have unveiled the benefits of this technique, generally revealing surgical and oncological outcomes that are equal to those of open surgery[12,13]. Minimally invasive surgeries have evolved for the purpose of further reducing postoperative complications and enhanced recovery. Intrducing minimally invasive esophagectomy (MIE) for esophageal cancer has some potential benefits over conventional open esophagectomy (OE). In this article, we reviewed the existing evidence and rationale for minimally invasive surgeries of EGJ cancer.
Although, the optimal surgical approach for these tumors remains under debate, three main surgical approaches are applied in the resection of EGJ tumors: transthoracic esophagectomy (the right transthoracic approach and the left transthoracic approach), transhiatal esophagectomy, and total gastrectomy. All three approaches enable a minimally invasive approach to be pursued. Irrespective of the surgical method and tumor stage, complete removal of the primary tumor is most relevant to prognosis.
The right transthorathic approach is possible to ensure a sufficient proximal margin even in EGJ cancer with long esophageal invasion. The upper mediastinal LNs can be removed by this approach. However, because of the surgical stress associated with thoracotomy, careful management is required to avoid postoperative pneumonia. There are two types of left transthorathic approaches in open surgery: the left thoracoabdominal approach, with an oblique incision from the left thorax to the abdomen, and left thoracophrenolaparotomy, which includes laparotomy and transdiaphragmatic thoracotomy. The one of the merit of these techniques is no requirement of repositioning during surgery. However, it is not possible to dissect the upper and middle mediastinal LNs with these approach.
The transhiatal approach, consists of transhiatal surgery on the abdomen and lower mediastinum and does not require thoracotomy. The procedures in the lower mediastinum include lower esophagectomy and only peri-esophageal LN dissection. Respiratory damage appears to be less than with the other approaches. Although en bloc dissection of the lower mediastinal LNs is possible, the surgical view of the mediastinum of this approach in open surgery is worse compared with the other approaches.
In general, Siewert type I cancer should be treated with en bloc transthoracic or transhiatal resection. The transthoracic approach is most beneficial, especially in advanced Siewert type I cancer, and the appropriate extent of lymphadenectomy (two-field Ivor-Lewis esophagectomy or three-field McKeown esophagectomy) remains a focus of discussion[16,17]. Generally, transhiatal esophagectomy has limitations due to the inability of mediastinal lymphadenectomy and should therefore be applied for frail patients.
The standard surgical approach for Siewert type II and type III cancers involves total gastrectomy with D2 lymphadenectomy. In Siewert type II, it involves the transhiatal resection of the distal esophagus with lower mediastinal lymphadenectomy. Splenectomy and pancreatectomy are not essential if the tumor is not located along the greater curvature and harbors metastasis of the no. 4sb lymph nodes. Furthermore, in Siewert type II and III early cancers, recent evidence suggests that proximal gastric resection with D1 + lymphadenectomy may contribute to avoid postgastrectomy syndrome without a detrimental effect on complete oncologic clearance.
Finally, minimally invasive approaches have been developed as a safe and feasible alternative to traditional open surgery for the treatment of esophageal cancer[20,21]. Efforts have been made by surgeons to establish all types of minimally invasive surgery (MIS), including minimally invasive Ivor-Lewis, McKeown esophagectomy, and transhiatal esophagectomy. An en bloc lymphadenectomy method in the upper and middle mediastinum with a single-port mediastinoscopic cervical approach that was recently developed by a Japanese surgeon is a hot topic in the treatment of EGJ cancer . In combination with lower mediastinal lymph nodes dissection using laparoscopic trans hiatal approach, they perform total mediastinal lymphadenectomy under pneumomediastinum assistance without thoracotomy. This technique achieves minimum invasiveness and has curative potential. Further investigation is needed to evaluate its safety and feasibility.
Table 1 summarized the cited results in this manuscript. Schoppmann et al. described a case controlled study (n = 31) that demonstrated higher rates of morbidity, transfusion rate, and postoperative respiratory complications in MIE comparing to OE. Briez et al. evaluated the impact of a hybrid MIE (HMIE, laparoscopic gastric mobilization and open thoracotomy, n = 140) to OE (n = 140) on respiratory complications. They found that the incidence of respiratory complications at 30 days after HMIE was significantly lower in comparison to OE. Moreover, the in-hospital mortality and overall morbidity rates were significantly lower in the HMIE group. Luketich et al. reviewed 1,033 consecutive patients undergoing MIE and revealed reduced blood loss, reduced post-operative complications and a shorter hospital stay, with same oncological outcomes. Seeing et al. compared the short-term surgical results of OE (n = 433) with MIE (n = 433) after propensity score matching. Although OE and MIE showed similar rates of mortality and pulmonary complications, anastomotic leakage and reintervention was more frequently observed after MIE. However, MIE was associated with a shorter length of hospitalization . The problem of their study was that the complication rates in both groups (62.6% after OE and 60.2% after MIE) were relatively high in comparison to historical studies[25,26,27]. Maas et al. also demonstrated that minimally invasive transhiatal esophagectomy by a laparoscopic approach (n = 50) is feasible and has the comparable oncologic outcome as open transhiatal esophagectomy (n = 50), and a shorter hospital and intensive care unit stay with a similar operation time (300 vs. 280 min, P = 0.110). Other retrospective reviews have also revealed that MIE is safe without compromising oncologic outcomes in comparison to the OE[29-33].
Summary of the cited results
|Schoppmann||23||62||esophagus or EGJ||MIE, HMIE (I, M)||RS||higher rates of morbidity, transfusion, and respiratory complications in MIE|
|Briez||24||280||mid- or distal esophagus||HMIE (I)||RS||lower rates of respiratory complications, in-hospital mortality, and overall morbidity rates after HMIE|
|Luketich||9||1,011||esophagus or EGJ||MIE (I, M)||RS||reduced blood loss and post-operative complications, and a shorter LOS in MIE|
|Seeing||25||866||esophagus or EGJ||MIE (I, M)||PMA||shorter LOS, but higer rates of anastomotic leakage and reintervention in MIE.|
|Maas||28||100||distal esophagus or EGJ||MIE (T)||RS||shorter hospital and intensive care unit stay with a similar operation time in MIE|
|Dantoc||34||1,598||esophagus or EGJ||MIE, HMIE (I, M)||SR||higher number of dissected lymph nodes in MIE with no difference in 5-year survival rates|
|Mamidanna||35||7,502||esophagus or EGJ||MIE, HMIE (I, M)||RS||higher reintervention rate in MIE, but no difference in 30-day mortality and overall medical morbidity|
|Zhou||36||14,311||esophagus or EGJ||MIE, HMIE (I, M)||MA||lower rate of in-hospital mortality, pulmonary complications, and arrhythmia in MIE|
|Luketich||14||95||mid- or distal esophagus||MIE (I, M)||PS||low peri-operative morbidity and mortality in MIE|
|Biere||37||115||esophagus or EGJ||MIE (I, M)||RCT||lower rates of respiratory complications, a shorter LOS and better QOL scores in MIE|
|Mariette||38||207||mid- or distal esophagus||HMIE (I)||RCT||reduced the rate of postoperative complications and improved morbidity with better global health in MIE|
|Sihag||40||3,780||esophagus||MIE (I, T)||PMA||longer operation times, higher rates of reoperation, but a shorter LOS in MIE|
|Yerokun||41||4,574||mid- or distal esophagus||MIE (I, M)||RS||higher number of exracted lymph nodes and shorter LOS in MIE|
|Shanmugasundaram||42||573||esophagus or EGJ||MIE (M)||MA||reduced incidence of respiratory complication, bleeding, LOS, but a longer operating time in MIE|
Dantoc et al. reported a systematic review of 17 case-control studies that compared total minimally invasive (thoracoscopy “and” laparoscopy, n = 494) or hybrid MIE (thoracoscopy “or” laparoscopy, n = 386) to OE (n = 718) for esophageal or EGJ cancer. In comparison to OE, MIE and HMIE had a higher number of dissected lymph nodes, while the overall 5-year survival rates of the OE and MIE/HMIE groups did not differ to a statistically significant extent. Mamidanna et al. investigated a population-based national study evaluating the short-term outcomes following OE (n = 6347) vs. MIE (n = 1155) for cancer in England. No differences were observed between the OE and MIE groups with regard to 30-day mortality and overall medical morbidity. The reintervention rate of the MIE group was higher than that of the OE group. Zhou et al. reported a meta-analysis of 48 studies involving 14,311 cases of resectable esophageal or EGJ cancer. In comparison to patients undergoing OE (n = 9,973), those undergoing MIE/HMIE (n = 4,509) had a significantly lower rate of in-hospital mortality. Patients undergoing MIE also had significantly lower rates of pulmonary complications and arrhythmia. The limitation of this study was that almost all of the included studies were non-randomized case-control studies (RCTs, n = 1; observational studies, n = 47), with a diversity of study designs and surgical interventions. They concluded that MIE should be the first-choice surgery for esophageal cancer patients. However, these findings must be interpreted cautiously due to the selection bias, as the patients selected for MIE had early-stage cancer with better physical status.
Luketich et al. conducted a multi-center, phase II, prospective study that revealed that MIE (n = 95) is feasible with low peri-operative morbidity (49.5%) and mortality (2.1%), and a 3-year overall survival rate of 58.4% Biere et al. conducted a randomized trials of MIE vs. OE for patients with esophageal or EGJ cancer. In this study, 59 patients were randomized to the MIE group and 56 patients were randomized to the OE group. They revealed the advantages of MIE over OE, including a reduced incidence of postoperative pulmonary infections, a shorter length of hospitalization and better quality of life scores, indicating improved patient recovery. Mariette et al. conducted a multicenter, randomized controlled trial that included 207 patients (MIRO trial). They investigated a HMIE using thoracotoic chest access with laparoscopy for abdominal access. In comparison to Ivor-Lewis resection, HMIE reduced the rate of postoperative complications and improved morbidity with an equivalent number of dissected lymph nodes, and no difference in resectability and curability. In the OE group, 64.4% of the patients had major postoperative morbidity in comparison to 35.9% in the HMIE group (P < 0.01). The incidence of pulmonary complications was 30.1% in the OE group and 17.7% in the HMIE group (P < 0.05). The 30-day mortality rate was 4.9% in both arms. They also reported a one-year follow-up results of the quality of life with their RCT participants and demonstrated that the MIE group had a better physical component, global health, and postoperative pain. A propensity score matched analysis of 3,780 patients who underwent OE or MIE for esophageal cancer by both transhiatal and Ivor-Lewis approaches demonstrated that OE and MIE had similar rates of morbidity and mortality. MIE was associated with longer operation times, higher rates of reoperation, and empyema, but a shorter median length of hospitalization. OE was associated with higher rates of wound infection, postoperative transfusion, and ileus.
Yerokun et al. investigated the predictive factors associated with the use of minimally invasive approaches (n = 1,308) for patients in the National Cancer Database who underwent resection of middle and distal esophageal cancers (n = 4,266). In the MIE group, the number of lymph nodes examined was significantly higher (15 vs. 13; P = 0.016) and the hospital stay was significantly shorter (10 days vs. 11 days; P = 0.046), however the rates of resection margin positivity, readmission, postoperative mortality, and, 3-year survival were comparable. With regard to oncological safety, no differences were found in OS or disease-free survival after 1 and 3 years of follow-up, with a better quality of life of physical components at 1 and 3 years of follow-up[33,39]. Thus, they concluded that MIE is considered to be a safe surgical approach and the majority of patients with a resectable cancer of esophagus or EGJ should be treated with MIE.
Shanmugasundaram et al. reported a meta-analysis of 4 studies involving 573 cases of resectable esophageal or EGJ cancer. In comparison to patients undergoing OE (n = 9,973), those undergoing McKeown’s-MIE (n = 4,509) had a significantly lower rates of pulmonary complications, less blood loss, and a shorter duration of hospital stay but a longer operating time.
However, since the current literatures are still limited, further large scale RCTs are needed. Thus, at present, the surgical method should be decided is at the surgeon’s discretion.
The introduction of surgical robots has shown the potential to expand the capabilities of performing complex operations through improved visualization and maneuverability. Recently, many surgeons have found robot-assisted thoracoscopic and transhiatal esophagectomy to be safe and acceptable for the treatment of esophageal and gastric cancer. Future randomized trials are expected to establish this procedure as one of the best approaches for esophageal and gastric cancer. Robotic surgery will be described in greater detail in another chapter.
The incidence of cancer of EGJ has increased in worldwide. This article reviews MIE for cancer of EGJ. All major approaches for the resection of EGJ cancer can be pursued by MIS. EGJ adenocarcinoma is traditionally classified by the Siewert classification system, although which has some limitations. The definition and classification of EGJ cancer remains controversial. MIE has emerged as a promising approach that might reduce the postoperative complications in comparison to open techniques. The advantages of MIE as a treatment for EGJ cancer in comparison to OE included a reduced hospitalization, and rate of pulmonary complications, and an improved quality of life with a similar nodal harvest, margin status, and 1- and 3-year survival rates. However, since the current literature is still limited, the selection of surgical method should be judged by the experienced surgeons. In any type of EGJ cancer, R0 radical resection is mandatory for improving the patient’s prognosis. Minimally invasive Ivor-Lewis or McKeown esophagectomy are the treatments of choice for Siewert type I cancer. Transhiatal esophagectomy is a surgical option for frail patients, which is limited because the operator cannot perform mediastinal lymphadenectomy. Single-port mediastinoscope-assisted transhiatal esophagectomy with mediastinal lymphadenectomy is an emerging minimally invasive approach that also has curative potential. Laparoscopic total (or proximal) gastrectomy is the optimal surgery for Siewert type III cancer, whereas both laparoscopic gastrectomy (with lower esophagectomy) and a minimally invasive Ivor-Lewis approach are the optimal minimally invasive choices for Siewert type II cancer. With the introduction of robotic surgery, esophagectomy is expected to evolve even further.
In conclusion, since the current literature is still limited, further well-desined RCTs are needed to clarify the optimal minimally invasive surgery for EGJ cancer.
Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Shibao K, Hirata K
Performed data acquisition, as well as provided administrative, technical, and material support: Mitsuyoshi M, Matayoshi N, Inoue Y, Katsuki T, Sato NAvailability of data and materials
Not applicable.Financial support and sponsorship
None.Conflicts of interest
All authors declared that there are no conflicts of interest.Ethical approval and consent to participate
Not applicable.Consent for publication
© The Author(s) 2019.
1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19:5598-606.DOIPubMedPMC
2. Buas M, Vaughan T. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013;23:3-9.DOIPubMedPMC
3. Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg 2017;6:131-6.DOIPubMedPMC
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.DOIPubMedPMC
5. In: Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours 8th ed. JOHN WILEY & SONS, LTD; 2017.
6. Kulig P, Sierzega M, Pach R, Kolodziejczyk P, Kulig J, et al. Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location. Eur J Surg Oncol 2016;42:1215-21.DOIPubMed
7. de Manzoni G, Pedrazzani C, Pasini F. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg 2002;73:1035-40.DOIPubMed
8. Cuschieri A, Shimi S, Banting S. Endoscopic oesophagectomy through a right thoracoscopic approach. J R Coll Surg Edinb 1992;37:7-11.PubMed
9. Luketich JD, Pennathur A, Awais O, Levy RM, Keeley S, et al. Outcomes After Minimally Invasive Esophagectomy Review of Over 1000 Patients. Ann Surg 2012;256:95-103.DOIPubMedPMC
10. Levy RM, Trivedi D, Luketich JD. Minimally invasive esophagectomy. Surg Clin North Am 2012;92:1265-85.DOIPubMed
11. Kitano S, Iso Y, Moriyama M. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994;4:146-8.PubMed
12. Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 2005;19:168-73.DOIPubMed
13. Kim HH, Hyung WJ, Cho GS. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417-20.DOIPubMed
14. Luketich JD, Pennathur A, Franchetti Y, Catalano PJ, Swanson S, et al. Minimally invasive esophagectomy: results of a prospective phase II multicenter trial- the Eastern cooperative oncology group (E2202) study. Ann Surg 2015;261:702-7.DOIPubMedPMC
15. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006;15:751-64.DOIPubMed
16. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.DOIPubMed
17. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000.DOIPubMed
18. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 2017;265:277-83.DOIPubMed
19. Zhao P, Xiao SM, Tang LC, Ding Z, Zhou X, et al. Proximal gastrectomy with jejunal interposition and TGRY anastomosis for proximal gastric cancer. World J Gastroenterol 2014;20:8268-73.DOIPubMedPMC
20. Wei MT, Zhang YC, Deng XB, Yang TH, He YZ, et al. Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis. World J Gastroenterol 2014;20:10183-92.DOIPubMedPMC
21. Guo W, Ma L, Zhang Y, Ma X, Yang S, et al. Totally minimally invasive Ivor-Lewis esophagectomy with single-utility incision video-assisted thoracoscopic surgery for treatment of mid-lower esophageal cancer. Dis Esophagus 2016;29:139-45.DOIPubMed
22. Fujiwara H, Shiozaki A, Konishi H, Kosuga T, Komatsu S, et al. Perioperative outcomes of single-port mediastinoscope-assisted transhiatal esophagectomy for thoracic esophageal cancer. Dis Esophagus 2017;30:1-8.DOIPubMed
23. Schoppmann SF, Prager G, Langer FB, Riegler FM, Kabon B, et al. Open versus minimally invasive esophagectomy: a single-center case controlled study. Surg Endosc 2010;24:3044-53.DOIPubMed
24. Briez N, Piessen G, Torres F, Lebuffe G, Triboulet JP, et al. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg 2012;99:1547-53.DOIPubMed
25. Seesing MFJ, Gisbertz SS, Goense L, van Hillegersberg R, Kroon HM, et al. A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the netherlands. Ann Surg 2017;266:839-46.DOIPubMed
26. Stark SP, Romberg MS, Pierce GE, Hermreck AS, Jewell WR, et al. Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Am J Surg 1996;172:478-81. discussion 481-2PubMed
27. Yamamoto M, Weber JM, Karl RC, Meredith KL. Minimally invasive surgery for esophageal cancer: review of the literature and institutional experience. Cancer Control 2013;20:130-7.DOIPubMed
28. Maas KW, Biere SS, Scheepers JJ, Gisbertz SS, van-der-Peet DL, et al. Laparoscopic versus open transhiatal esophagectomy for distal and junction cancer. Rev Esp Enferm Dig 2012;104:197-202.PubMed
29. Santillan AA, Farma JM, Meredith KL, Shah NR, Kelley ST. Minimally invasive surgery for esophageal cancer. J Natl Compr Canc Netw 2008;6:879-84.DOIPubMed
30. Verhage RJ, Hazebroek EJ, Boone J, Van Hillegersberg R. Minimally invasive surgery compared to open procedures in esophagectomy for cancer: a systematic review of the literature. Minerva Chir 2009;64:135-46.PubMed
31. Safranek PM, Cubitt J, Booth MI, Dehn TC. Review of open and minimal access approaches to oesophagectomy for cancer. Br J Surg 2010;97:1845-53.DOIPubMed
32. Singh RK, Pham TH, Diggs BS, Perkins S, Hunter JG. Minimally invasive esophagectomy provides equivalent oncologic outcomes to open esophagectomy for locally advanced (stage II or III) esophageal carcinoma. Arch Surg 2011;146:711-4.DOIPubMed
33. Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, et al. Minimally invasive versus open esophageal resection: three- year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann Surg 2017;266:232-36.DOIPubMed
34. Dantoc MM, Cox MR, Eslick GD. Does minimally invasive esophagectomy (MIE) provide for comparable oncologic outcomes to open techniques? A systematic review. J Gastrointest Surg 2012;16:486-94.DOIPubMed
35. Mamidanna R, Bottle A, Aylin P, Faiz O, Hanna GB. Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg 2012;255:197-203.DOIPubMed
36. Zhou C, Zhang L, Wang H, Ma X, Shi B, et al. Superiority of minimally invasive oesophagectomy in reducing in-hospital mortality of patients with resectable oesophageal cancer: a meta-analysis. PLoS one 2015;10:e0132889.DOIPubMedPMC
37. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887-92.DOIPubMed
38. Mariette C, Meunier B, Pezet D, Dalban C, Collet D, et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open- label, randomized phase III controlled trial, the MIRO trial. J Clinic Oncol 2015;33:suppl 5.DOI
39. Maas KW, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, et al. Quality of life and late complications after minimally invasive compared to open esophagectomy: results of a randomized trial. World J Surg 2015;39:1986-993.DOIPubMedPMC
40. Sihag S, Kosinski AS, Gaissert HA, Wright CD, Schipper PH. Minimally invasive versus open esophagectomy for esophageal cancer: a comparison of early surgical outcomes from the society of thoracic surgeons national database. Ann Thorac Surg 2016;101:1281-8.DOIPubMed
41. Yerokun BA, Sun Z, Yang CJ, Gulack BC, Speicher PJ, et al. Minimally invasive versus open esophagectomy for esophageal cancer: a population-based analysis. Ann Thorac Surg 2016;102:416-23.DOIPubMedPMC
42. Shanmugasundaram R, Hopkins R, Neeman T, Beenen E, Fergusson J, et al. Minimally invasive McKeown's vs open oesophagectomy for cancer: a meta-analysis. Eur J Surg Oncol 2019;45:941-9.DOIPubMed
43. Seto Y, Mori K, Aikou S. Robotic surgery for esophageal cancer: merits and demerits. Ann Gastroenterol Surg 2017;14:193-8.DOIPubMedPMC